Caseware UK (AP4) 2025.0.111 2025.0.111 2025-12-312025-12-31true2024-12-17falseNo description of principal activity00The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false SC832066 2024-12-16 SC832066 2024-12-17 2025-12-31 SC832066 2023-12-17 2024-12-16 SC832066 2025-12-31 SC832066 c:Director1 2024-12-17 2025-12-31 SC832066 d:CurrentFinancialInstruments 2025-12-31 SC832066 c:Micro-entities 2024-12-17 2025-12-31 SC832066 c:AuditExempt-NoAccountantsReport 2024-12-17 2025-12-31 SC832066 c:FullAccounts 2024-12-17 2025-12-31 SC832066 c:PrivateLimitedCompanyLtd 2024-12-17 2025-12-31 SC832066 e:PoundSterling 2024-12-17 2025-12-31 iso4217:GBP xbrli:pure

Registered number: SC832066










RINN THERAPEUTICS LIMITED








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE PERIOD ENDED 31 DECEMBER 2025
 
RINN THERAPEUTICS LIMITED
REGISTERED NUMBER: SC832066

BALANCE SHEET
AS AT 31 DECEMBER 2025

2025
£


Current assets
160,657

Creditors: amounts falling due within one year
(221,208)

Net current liabilities
 
 
(60,551)

Total assets less current liabilities
(60,551)


Net liabilities
(60,551)



Capital and reserves
(60,551)


Notes


General information

Rinn Therapeutics Limited is a private company limited by shares incorporated in England and Wales. The registered office is 137a George Street, Edinburgh, EH2 4JY.


Average number of employees

The average monthly number of employees, including directors, during the period was 0.

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the period in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to entities subject to the micro-entities' regime.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




Mr P Finan
Director

Date: 17 September 2026

Page 1
 
RINN THERAPEUTICS LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2025

1.Accounting policies

 
1.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 105 the UK and the Republic of Ireland and the Companies Act 2006.

The financial statements are presented in Pounds Sterling (£), which is the company's functional currency. Monetary amounts in these financial statements are rounded to the nearest £1.

 
1.2

Going concern

The directors are satisfied that on the basis of the anticipated continued support from current investors, the company will have sufficient resources to enable it to meet its liabilities as they fall due for at least 12 months from the date of signing these financial statements. 

The directors consider it is therefore appropriate to prepare the financial statements on the going concern basis.


Page 2